<DOC>
	<DOCNO>NCT00016276</DOCNO>
	<brief_summary>Randomized phase III trial compare effectiveness combination chemotherapy , surgery , radiation therapy without dexrazoxane trastuzumab treat woman stage IIIA , stage IIIB stage IV breast cancer . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Chemoprotective drug , dexrazoxane , may protect normal cell side effect chemotherapy . Monoclonal antibody trastuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Radiation therapy use high-energy x-rays damage tumor cell . It yet know chemotherapy combine surgery radiation therapy effective without dexrazoxane trastuzumab treat breast cancer</brief_summary>
	<brief_title>Combination Chemotherapy , Surgery , Radiation Therapy With Without Dexrazoxane Trastuzumab Treating Women With Stage III Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine time locoregional recurrence , time completion treatment , overall survival woman HER-2+ stage IIIA IIIB regional stage IV breast cancer treat doxorubicin cyclophosphamide without dexrazoxane , follow paclitaxel without trastuzumab ( Herceptin ) , follow surgery radiotherapy without trastuzumab . II . Determine whether addition trastuzumab paclitaxel therapy improve response 24 week therapy patient . III . Determine whether addition trastuzumab paclitaxel therapy increase rate cardiotoxicity patient . IV . Determine whether addition dexrazoxane doxorubicin cyclophosphamide compromise response patient . V. Determine whether addition dexrazoxane doxorubicin cyclophosphamide reduces rate cardiotoxicity patient . VI . Determine whether long-term trastuzumab local therapy improve disease-free survival patient . VII . Determine whether long-term trastuzumab local therapy increase rate cardiotoxicity patient . VIII . Determine occurrence grade 3 high toxicity , second malignancy , acute myelogenous leukemia , myelodysplastic syndrome patient treat regimen . IX . Determine eventual rate breast conservation patient consider candidate breast conservation prior neoadjuvant treatment . X . Determine clinical response doxorubicin cyclophosphamide without dexrazoxane clinical/mammographic/ultrasound response paclitaxel without trastuzumab , compare pathologic response definitive surgery patient . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord stage ( inflammatory v noninflammatory inoperable stage III/ regional stage IV v operable stage III ) . Patients randomize 1 8 treatment arm . Arm I : Patients receive dexrazoxane IV 10-20 minute , doxorubicin IV 5-10 minute , cyclophosphamide IV 30 minute day 1 , 22 , 43 , 64 . Patients receive paclitaxel IV 1 hour trastuzumab ( Herceptin ) IV 30-90 minute day 85 , 92 , 99 , 106 , 113 , 120 , 127 , 134 , 141 , 148 , 155 , 162 . Approximately 1-2 week completion neoadjuvant chemotherapy , patient undergo breast conservation surgery , modify radical mastectomy , mastectomy . Patients unacceptable toxicity locoregional disease progression may undergo surgery prior week 24 ( i.e. , completion neoadjuvant chemotherapy ) . Beginning 2-4 week breast conservation surgery 3-5 week mastectomy , patient undergo radiotherapy daily 5 day week 6-8 week . Patients receive long-term trastuzumab IV 30-90 minute weekly 40 week begin week 36 ( day 254 ) . Arm II : Patients receive dexrazoxane , doxorubicin , cyclophosphamide arm I . Patients receive paclitaxel ( without trastuzumab ) arm I . Patients undergo surgery radiotherapy arm I . Patients receive long-term trastuzumab arm I . Arm III : Patients receive dexrazoxane , doxorubicin , cyclophosphamide arm I . Patients receive paclitaxel trastuzumab arm I . Patients undergo surgery radiotherapy arm I . Patients undergo observation 40 week completion radiotherapy . Arm IV : Patients receive dexrazoxane , doxorubicin , cyclophosphamide arm I . Patients receive paclitaxel arm II . Patients undergo surgery radiotherapy arm I . Patients undergo observation arm III . Arm V : Patients receive doxorubicin cyclophosphamide ( without dexrazoxane ) arm I . Patients receive paclitaxel trastuzumab arm I . Patients undergo surgery radiotherapy arm I . Patients receive long-term trastuzumab arm I . Arm VI : Patients receive doxorubicin cyclophosphamide arm V. Patients receive paclitaxel arm II . Patients undergo surgery radiotherapy arm I . Patients receive long-term trastuzumab arm I . Arm VII : Patients receive doxorubicin cyclophosphamide arm V. Patients receive paclitaxel trastuzumab arm I . Patients undergo surgery radiotherapy arm I . Patients undergo observation arm III . Arm VIII : Patients receive doxorubicin cyclophosphamide arm V. Patients receive paclitaxel arm II . Patients undergo surgery radiotherapy arm I . Patients undergo observation arm III . Treatment continue arm absence distant disease progression . Beginning within 12 week completion neoadjuvant chemotherapy , hormone receptor-positive patient may receive oral tamoxifen daily 5 year . Patients follow every 6 month 5 year annually 5 year . PROJECTED ACCRUAL : A total 396 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Razoxane</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Dexrazoxane</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm primary infiltrating adenocarcinoma breast Confirmed core needle biopsy incisional biopsy Amplification HER2 FISH Overexpression ( 3+ ) HER2 immunohistochemistry Staging criterion complete clinical radiographic staging : T3 , N1 , M0 Any T , N2 N3 , M0 T4 , N , M0 , include clinical pathological inflammatory disease Regional stage IV disease supraclavicular infraclavicular lymph node site metastasis Measurable evaluable disease Prior ductal carcinoma situ ipsilateral breast allow treated excision without mastectomy radiation Metaplastic carcinoma allow Synchronous bilateral primary disease allow ( provide least 1 cancer meet stag criterion ) No dermal lymphatic involvement clinical inflammatory change Hormone receptor status : Estrogen receptor positive negative Progesterone receptor positive negative Female Granulocyte count least 1,000/mm^3 Platelet count least 100,000/mm^3 Bilirubin great upper limit normal ( ULN ) AST great 2 time ULN Creatinine great 1.5 time ULN LVEF normal MUGA No uncontrolled severe cardiovascular disease ( e.g. , myocardial infarction within past 6 month , congestive heart failure treat medication , uncontrolled hypertension ) No currently active malignancy except nonmelanoma skin cancer Not pregnant nursing Fertile patient must use effective contraception Patients take tamoxifen must use effective nonhormonal contraception 2 month study No prior chemotherapy No concurrent chemotherapy No 4 week prior tamoxifen disease Prior tamoxifen raloxifene longer 4 week chemoprevention allow No concurrent tamoxifen raloxifene No concurrent hormonal therapy except steroid adrenal failure , hormone nondiseaserelated condition ( e.g. , insulin diabetes ) , intermittent dexamethasone antiemetic See Disease Characteristics No prior radiotherapy index malignancy No prior radiotherapy ipsilateral breast , regional node , mediastinum , heart Prior radiotherapy contralateral breast ductal carcinoma situ early stage invasive breast cancer allow provide earlier radiotherapy preclude optimal delivery study radiotherapy criterion low risk metastasis first malignancy meet See Disease Characteristics No prior sentinel lymph node biopsy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>